---
title: "Tevogen Bio Holdings Inc. (TVGN.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/TVGN.US.md"
symbol: "TVGN.US"
name: "Tevogen Bio Holdings Inc."
industry: "Biotechnology"
datetime: "2026-05-21T11:56:11.065Z"
locales:
  - [en](https://longbridge.com/en/quote/TVGN.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/TVGN.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/TVGN.US.md)
---

# Tevogen Bio Holdings Inc. (TVGN.US)

## Company Overview

Tevogen Bio Holdings Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in Phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 patients with a B cell cancer indication, as well as Long COVID prevention and treatment. It is also developing TVGN 920 which is in preclinical trial for treating cervical cancer; TVGN 960 which is in preclinical trial for treating oropharyngeal cancer; TVGN 601 which is in preclinical trial for treating multiple sclerosis; TVGN 930 which is in preclinical trial for treating Epstein-Barr virus associated lymphomas; and TVGN 116 a product candidate targeted at hepatitis B and is in preclinical trial. Tevogen Bio Holdings Inc.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [evogen.com](https://evogen.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -1.99 | 242 | - | - | - |
| PB | -2.34 | 497 | - | - | - |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-03-04T05:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Hold | 1 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 10.48 |
| Highest Target | 100.00 |
| Lowest Target | 100.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/TVGN.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/TVGN.US/norm.md)
- [Related News](https://longbridge.com/en/quote/TVGN.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/TVGN.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**